Papers/PMID:32846786
Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.
Medicine2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
spironolactone — decreases 24-hour ambulatory systolic blood pressure
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared with placebo and no treatment, spironolactone significantly reduced the 24-hour ambulatory SBP (WMD = −10.31, 95% CI = −12.86 to −7.76, P <.001) (WMD = −11.00, 95% CI = −19.25 to −2.75).”
Quoted verbatim from Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Patients with resistant hypertension, spironolactone added to background antihypertensive therapy versus placebo and versus no treatment, pooled from randomised trials
Effect -10.31 mean difference, 95% CI -12.86 to -7.76
Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.2020PMID:32846786Permalink